Advanced Therapy Commercialization

Comprehensive service programs for the development of Cell and Gene Therapy (CGT), mRNA, and other advanced therapies from concept to commercial. Offering expertise and support in discovery, characterization, preclinical CRO safety testing, and scalable manufacturing in an integrated, innovation-rich environment that exceeds the value proposition offered by traditional CDMO and PDMO contract models.

Advanced Therapies Discovery and Characterization

AmplifyBio offers a comprehensive range of development and discovery services, with particular expertise in T cell therapy including TCR-T and CAR-T therapies, immunotherapy, plasmid design and development, protein engineering, mRNA therapeutics, and non-viral gene editing.

With a deep commitment to advancing therapeutic innovation, AmplifyBio offers not just a list of assay capabilities or R&D programs but rather, human experts with state-of-the-art platforms and real experience bringing novel drugs to the clinic. With our technology-integrated experience, we are poised to meet the complex needs of biotech and pharmaceutical companies. 

Deep understanding of product functionality, efficacy and characteristics are the key to mitigating downstream development risks. Read more about AmplifyBio’s The Product is the Product™ promise.

  • Engineering of therapeutic proteins and protein-based tools
  • Designing viral vectors
  • Non-viral gene editing and payload development
  • Functional and phenotypic characterization
  • Identification of tumor antigens
  • T-cell and T-cell receptor biology
  • Identification and verification of edits to T-cells
  • Immune Monitoring
ADOC Shot
AMEC 9

Advanced Therapy Manufacturing

Partnering with AmplifyBio for your manufacturing needs for cell therapy, gene therapy, mRNA, plasmid, or other complex supply chain components differs from a typical CDMO experience. Instead, drug developers will find an innovation-rich ecosystem designed to advance a diverse range and class of pharmaceutical products across development stages.  Available in 3 collaborative, partner-driven staffing models: 

  • Hoteling Model
  • Hybrid SME+ Model
  • Full-Service Partner Model
DSC9737

Additional Preclinical CRO and CDMO Services

Contact Us

Comprehensive service programs for the development of Cell and Gene Therapy (CGT), mRNA, and other advanced therapies from concept to commercial. Offering expertise and support in discovery, characterization, preclinical CRO safety testing, and scalable manufacturing available in an integrated, innovation-rich environment that goes beyond the value proposition offered by traditional CDMO and PDMO contract models.